Liposomal Bupivacaine, FDA approved local anesthetic injectable liposomal suspension intended for the post-surgical pain management. In the present study, researchers aimed to determine the cumulative postoperative vaginal pain between the test medication (extended-release liposomal Bupivicaine) group to placebo (saline) group. Study Design: Randomized, double-blinded, placebo-controlled trial was carried out with 100 subjects. The mean age of the subjects was 18 years.
The subjects underwent surgery involving the posterior vaginal wall or muscularis. Subjects received 20 ml of liposomal bupivacaine and 20ml of placebo(saline) which were injected into the lateral vaginal wall/levator muscle area and into the perineal body. Methods Vaginal pain scores were measured by the Defense and Veterans Pain Rating Scale, on days 1, 3, and 7, and cumulatively. Feedback from the patients was…
